ArticleBioengineering & translational medicine2025
Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity.
Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Opn3 Drives Blue-Light-Induced Reduction in Lipid Droplets and Antiviral Defense.Biomolecules · 2026Article
- Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity.Bioengineering & translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With papillary thyroid carcinoma (PTC) rates rising significantly, concerns about conventional treatments like thyroidectomy and radiotherapy highlight the need for non-invasive options. Our study explores photobiomodulation therapy (PBMT), which uses specific light wavelengths to evoke cellular responses in PTC treatment. Our research utilized a custom-designed optical system to investigate PBMT, finding that blue light at a wavelength of 465 nm can safely and effectively inhibit the proliferation of the TPC-1 PTC cell line by inducing cell cycle arrest. Additionally, we developed a wirelessly powered wearable PBMT device, which is equipped with an advanced light delivery system that ensures precise and consistent dosage. This device designed for optimal patient comfort, effectively suppressed tumor growth in mouse models without adverse effects. PBMT indicates thyroid tissue's light responsiveness as a non-visual organ. Our study's innovative approach integrates the disciplines of oncology, biophysics, and medical device technology, thereby advancing the treatment paradigms for PTC. This interdisciplinary bridge not only highlights our groundbreaking findings but also paves the way for future research in cancer therapy and photomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.